Plateletbio Completes $75.5M Series B Financing

Nov 04, 2021•almost 4 years ago

Amount Raised

$75.5 Million

Round Type

series b

Watertown

Description

PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology, today announced that it has raised $75.5 million in Series B financing. The round includes new investors SymBiosis, K2 HealthVentures and Oxford Finance as well as participation from existing investors Ziff Capital Partners and Qiming Venture Partners.

Company Information

Company

Platelet Bio

Location

Watertown, South Dakota, United States

About

Inspired by the biological function and versatility of platelets, PlateletBio is pioneering the next generation of safer, more effective cell therapies. Its cell therapy platform produces “platelet-like cells” (PLCs) capable of performing vital biological functions and able to be genetically engineered into multiple allogeneic cell therapies. The company, based in Watertown, Massachusetts, is focused on advancing a diverse pipeline of next-generation cellular therapies for applications in autoimmune diseases, hematology, and inflammation. Visit www.plateletbio.com for more information.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech